Literature DB >> 21447168

Salvage living donor liver transplantation after percutaneous transluminal angioplasty for recurrent Budd-Chiari syndrome: a case report.

Yusaku Shirai1, Hitoshi Yoshiji, Saiho Ko, Masaharu Yamazaki, Yasuhide Ikenaka, Ryuichi Noguchi, Chie Morioka, Kosuke Kaji, Yosuke Aihara, Keisuke Nakanishi, Junichi Yamao, Masahisa Toyohara, Akira Mitoro, Masayoshi Sawai, Motoyuki Yoshida, Masao Fujimoto, Masahito Uemura, Yoshiyuki Nakajima, Hiroshi Fukui.   

Abstract

INTRODUCTION: Budd-Chiari syndrome is a very rare pathological entity that ultimately leads to liver failure. Several therapeutic modalities, including percutaneous transluminal angioplasty, have been attempted to save the life of patients with Budd-Chiari syndrome. Few reports have described a salvage living donor liver transplantation performed after percutaneous transluminal angioplasty in a patient with acute Budd-Chiari syndrome. CASE
PRESENTATION: A 26-year-old Japanese man developed severe progressive manifestations, such as massive ascites and hematemesis due to rupture of esophageal varices. After making several investigations, we diagnosed the case as Budd-Chiari syndrome. We first performed percutaneous transluminal angioplasty to dilate a short-segment stenosis of his inferior vena cava. The first percutaneous transluminal angioplasty greatly improved the clinical manifestations. However, after a year, re-stenosis was detected, and a second percutaneous transluminal angioplasty failed to open the severe stricture of his inferior vena cava. Since our patient had manifestations of acute liver failure, we decided to perform salvage living donor liver transplantation from his brother. The transplantation was successfully performed and all clinical manifestations were remarkably alleviated.
CONCLUSION: In cases of recurrent Budd-Chiari syndrome, the blocked hepatic venous outflow is not always relieved, even with invasive therapies. We have to take into account the possibility of adopting alternative salvage therapies if the first therapeutic modalities fail. When invasive therapy such as percutaneous transluminal angioplasty fails, liver transplantation should be considered as an alternative option.

Entities:  

Year:  2011        PMID: 21447168      PMCID: PMC3078858          DOI: 10.1186/1752-1947-5-124

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  10 in total

Review 1.  The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies.

Authors:  Dominique-Charles Valla
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

Review 2.  The Budd-Chiari syndrome.

Authors:  K V Narayanan Menon; Vijay Shah; Patrick S Kamath
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

3.  Successful treatment of acute Budd-Chiari syndrome with percutaneous transluminal angioplasty.

Authors:  Y Shirai; H Yoshiji; M Fujimoto; H Kojima; K Yanase; T Namisaki; M Kitade; K Yamamoto; H Sakaguchi; K Kichikawa; H Fukui
Journal:  Abdom Imaging       Date:  2004-06-08

4.  Model for end-stage liver disease (MELD) exception for Budd-Chiari syndrome.

Authors:  W Kenneth Washburn; Robert G Gish; Patrick S Kamath
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

5.  Surgical techniques and long-term outcomes of living donor liver transplantation for Budd-Chiari syndrome.

Authors:  T Yamada; K Tanaka; Y Ogura; S Ko; Y Nakajima; Y Takada; S Uemoto
Journal:  Am J Transplant       Date:  2006-08-25       Impact factor: 8.086

6.  Bacterial peritonitis in hepatic inferior vena cava disease: a hypothesis to explain the cause of infection in high protein ascites.

Authors:  Santosh Shrestha; Shobhana Shrestha
Journal:  Hepatol Res       Date:  2002-09       Impact factor: 4.288

7.  Epidemiological and clinical features of Budd-Chiari syndrome in Japan.

Authors:  H Okuda; H Yamagata; H Obata; H Iwata; R Sasaki; F Imai; M Okudaira; M Ohbu; K Okuda
Journal:  J Hepatol       Date:  1995-01       Impact factor: 25.083

Review 8.  Budd-Chiari syndrome: illustrated review of current management.

Authors:  John D Horton; Francisco L San Miguel; Fernando Membreno; Francis Wright; Juan Paima; Preston Foster; Jorge A Ortiz
Journal:  Liver Int       Date:  2008-04       Impact factor: 5.828

9.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

Review 10.  Primary Budd-Chiari syndrome.

Authors:  Dominique-Charles Valla
Journal:  J Hepatol       Date:  2008-10-26       Impact factor: 25.083

  10 in total
  1 in total

Review 1.  Budd-Chiari syndrome and liver transplantation.

Authors:  Nobuhisa Akamatsu; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2015-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.